Oculis

Oculis is a global biopharmaceutical company on a mission to save sight and improve eye care through visionary innovation. Founded in 2014 and publicly listed on Nasdaq, the company has built a differentiated, late-stage pipeline targeting high-prevalence diseases with significant unmet needs, including diabetic macular edema (DME), dry eye disease (DED), and optic neuritis. Its strategy leverages proprietary technology platforms like OPTIREACH® to develop non-invasive topical treatments that challenge current invasive standards of care, positioning it as a potential leader in next-generation ophthalmology therapeutics.

OPTIREACH® is a solubilizing formulation technology designed to enable topical eye drops to penetrate and deliver therapeutic drug concentrations to both the front and back of the eye. The company also develops novel biologics and barrier-crossing small molecule peptoids for neuroprotection.

Faces entrenched competition from intravitreal injections in DME and multiple branded therapies in dry eye disease. Key differentiation is non-invasive administration (OCS-01) and novel mechanisms of action (Licaminlimab, Privosegtor). Privosegtor enjoys a first-mover advantage in neuroprotection with no approved competitors.